No • 50%

Yes • 50%

Yes • 50%

No • 50%

No • 50%

Yes • 50%

Stock price changes by less than 10% • 25%

Stock price increases by over 20% • 25%

Stock price decreases • 25%

Stock price increases by 10-20% • 25%

Not approved • 25%

Approval delayed • 25%

Approved without conditions • 25%

Approved with conditions • 25%

Trial inconclusive or delayed • 25%

Primary endpoint met with significant improvement • 25%

Primary endpoint met with moderate improvement • 25%

Primary endpoint not met • 25%